Benitec Biopharma (NASDAQ:BNTC) Now Covered by SVB Leerink

Equities researchers at SVB Leerink assumed coverage on shares of Benitec Biopharma (NASDAQ:BNTC) in a research report issued on Monday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $13.00 price target on the biotechnology company’s stock. SVB Leerink’s price objective points to a potential upside of 44.61% from the company’s previous close.

Several other research analysts have also weighed in on BNTC. Piper Sandler began coverage on shares of Benitec Biopharma in a research note on Thursday, June 13th. They set an “overweight” rating and a $30.00 price objective on the stock. JMP Securities upped their price objective on Benitec Biopharma from $10.00 to $16.00 and gave the company a “market outperform” rating in a research note on Monday, April 22nd.

Benitec Biopharma Stock Up 0.3 %

Shares of NASDAQ BNTC opened at $8.99 on Monday. Benitec Biopharma has a 52 week low of $1.86 and a 52 week high of $10.88. The stock has a 50 day moving average price of $8.36 and a 200 day moving average price of $6.12. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.18 and a quick ratio of 4.18.

Benitec Biopharma (NASDAQ:BNTC) last released its quarterly earnings data on Monday, May 13th. The biotechnology company reported ($1.64) EPS for the quarter. Equities analysts forecast that Benitec Biopharma will post -7.67 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Benitec Biopharma stock. Janus Henderson Group PLC grew its position in Benitec Biopharma Inc. (NASDAQ:BNTC) by 35.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 244,491 shares of the biotechnology company’s stock after purchasing an additional 64,092 shares during the quarter. Janus Henderson Group PLC owned about 9.44% of Benitec Biopharma worth $1,266,000 as of its most recent SEC filing. 52.19% of the stock is owned by institutional investors.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.